CEO Michael Halstead to participate in a fireside chat on Wednesday, September 16, 2026 at 8:30 a.m. EDT. NEW YORK and TORONTO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to
CEO Michael Halstead to participate in a fireside chat on Monday, September 14, 2026 at 9:00 a.m. EDT NEW YORK and TORONTO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping
CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. EDT. NEW YORK and TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping
Former Intra-Cellular Therapies, Inc. (“Intra-Cellular”) executives bring complementary experience in organizational scale-up, central nervous system (“CNS”) drug development, regulatory approvals and commercialization Ms. Donohue is the former Chief Human Resources Officer of Intra-Cellular, where
- Appointed Michael Halstead, former President of Intra-Cellular Therapies, as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization - - Completed enrollment in the Phase 3 APPROACH pivotal study of HLP003 in Major Depressive Disorder (“MDD”); topline
CEO Michael Halstead to participate in a fireside chat on Wednesday, August 12 at 12:00 p.m. EDT NEW YORK and TORONTO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping minds
Former President of Intra-Cellular Therapies, Inc. was instrumental in building and scaling the company, which was subsequently acquired by Johnson & Johnson Experienced executive with a proven track record of guiding pharmaceutical companies through late-stage clinical development and
Enrollment continues in EMBRACE, the second pivotal study of the Phase 3 PARADIGM Program Participant rollover is ongoing into the EXTEND long-term study generating long-term safety and durability data APPROACH topline data readout on track for Q4 2026 1,2 HLP003 previously granted Breakthrough
- Recently closed $50 million underwritten offering reinforces strong institutional investor conviction and bolsters balance sheet for execution of second Phase 3 HLP003 trial 1, 2,3, EMBRACE, for potential U.S. FDA New Drug Application in 2028 1,2,3 - - Phase 3 APPROACH pivotal study of HLP003 in
NEW YORK and TORONTO, June 25, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “ Company ” or “ Helus Pharma ”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“ NSAs ”), is pleased to announce that it
NEW YORK and TORONTO, June 24, 2026 (GLOBE NEWSWIRE) -- Helus Pharma™ (Nasdaq: HELP) (Cboe CA: HELP) (the “ Company ” or “ Helus Pharma ”), a clinical stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“ NSAs ”), is pleased to announce the
- APPROACH Phase 3 clinical trial of HLP003 for the adjunctive treatment of major depressive disorder (“MDD”) is progressing as planned and has surpassed 86% enrollment - - Phase 2 HLP003 data demonstrated long-term efficacy with ~23-point reduction in Montgomery-Asberg Depression Rating Scale